Cookies help us deliver our services. By using our services, you agree to our use of cookies.
Learn more
OK
Skip to main content (Press Enter).
Sign In
Skip auxiliary navigation (Press Enter).
Contact Us
Skip main navigation (Press Enter).
Toggle navigation
Search Options
About
What is the AMS
AMS International Scientific Committee
AMS North America Scientific Committee
AMS Educational Executive Committee
AMS Ambassadors
Certifications and Educational Credits
Upcoming Events
Videos & Webinars
International Events
Become a Speaker
Videos On Demand
Education 365
Preview AMS TV
Features
AMS Features
News & Publications
AMS Bookstore
Blogs
Industry
Industry Partners
Become a Sponsor
Features
Blogs
Blog Viewer
Blogs
Eczema control and treatment satisfaction in atopic dermatitis patients treated with dupilumab – a cross-sectional study from the BioDay registry
By
- AMS
posted
Jun 21, 2021 11:07 AM
0
Recommend
.
0 comments
1 view
Permalink
Related Content
The current treatment landscape in adult atopic dermatitis in the United States: results from a cross-sectional real-world study
- AMS
Added Mar 23, 2021
Blog Entry
The impact of COVID-19 pandemic on psoriasis patients, and their immunosuppressive treatment: a cross-sectional multicenter study from Turkey
- AMS
Added May 25, 2021
Blog Entry
Systemic treatment of psoriasis and psoriatic arthritis in the United States: a cross-sectional study
- AMS
Added Jul 27, 2020
Blog Entry
Dupilumab for atopic dermatitis: what are patients learning on YouTube?
- AMS
Added Apr 16, 2020
Blog Entry
Punctal stenosis associated with dupilumab therapy for atopic dermatitis
- AMS
Added Jan 08, 2020
Blog Entry
© 2022 AMS, Aesthetic Multispecialty Society. All Rights Reserved.
Powered by Higher Logic